Literature DB >> 2821684

Expression of biologically active and antigenically authentic parainfluenza type 3 virus hemagglutinin-neuraminidase glycoprotein by a recombinant baculovirus.

K L van Wyke Coelingh1, B R Murphy, P L Collins, A M Lebacq-Verheyden, J F Battey.   

Abstract

The hemagglutinin-neuraminidase (HN) gene of human type 3 parainfluenza virus has been inserted into a baculovirus expression vector under the control of the polyhedrin promoter. HN protein produced in insect cells by the recombinant baculovirus appeared to be glycosylated, was transported to the cell surface, and was biologically active. All of the HN epitopes previously mapped functionally to a region(s) involved in neuraminidase and/or hemagglutination activities were conformationally unaltered on the recombinant protein. The HN produced in this system also induced a protective immune response in immunized cotton rats. From these studies we conclude that the HN expressed in insect cells represents a source of authentic HN glycoprotein suitable for structural analysis and immunization.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2821684     DOI: 10.1016/0042-6822(87)90018-3

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  17 in total

1.  Synthesis of the membrane fusion and hemagglutinin proteins of measles virus, using a novel baculovirus vector containing the beta-galactosidase gene.

Authors:  J Vialard; M Lalumière; T Vernet; D Briedis; G Alkhatib; D Henning; D Levin; C Richardson
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

Review 2.  Expression of eukaryotic genes in insect cultures.

Authors:  M J Fraser
Journal:  In Vitro Cell Dev Biol       Date:  1989-03

3.  Expression of active secreted forms of human amyloid beta-protein precursor by recombinant baculovirus-infected insect cells.

Authors:  R Bhasin; W E Van Nostrand; T Saitoh; M A Donets; E A Barnes; W W Quitschke; D Goldgaber
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

4.  Cloning and expression of the HN gene from the velogenic viscerotropic Newcastle disease virus strain AF2240 in Sf9 insect cells.

Authors:  H K Ong; A M Ali; A R Omar; K Yusoff
Journal:  Cytotechnology       Date:  2000-03       Impact factor: 2.058

5.  Role of individual glycoproteins of human parainfluenza virus type 3 in the induction of a protective immune response.

Authors:  R Ray; B J Glaze; R W Compans
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

6.  Immunoselection of recombinant baculoviruses expressing high levels of biologically active herpes simplex virus type 1 glycoprotein D.

Authors:  H Ghiasi; A B Nesburn; R Kaiwar; S L Wechsler
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

7.  Posttranslational processing of endogenous and of baculovirus-expressed human gastrin-releasing peptide precursor.

Authors:  A M Lebacq-Verheyden; P G Kasprzyk; M G Raum; K Van Wyke Coelingh; J A Lebacq; J F Battey
Journal:  Mol Cell Biol       Date:  1988-08       Impact factor: 4.272

8.  Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus.

Authors:  K L van Wyke Coelingh; C C Winter; E L Tierney; S L Hall; W T London; H W Kim; R M Chanock; B R Murphy
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

9.  Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy.

Authors:  A P Durbin; M H Skiadopoulos; J M McAuliffe; J M Riggs; S R Surman; P L Collins; B R Murphy
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

10.  Expression of bovine herpesvirus 1 glycoprotein gIV by recombinant baculovirus and analysis of its immunogenic properties.

Authors:  S van Drunen Littel-van den Hurk; M D Parker; D R Fitzpatrick; T J Zamb; J V van den Hurk; M Campos; R Harland; L A Babiuk
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.